Literature DB >> 25081046

Pathogenic role of antibodies against monomeric C-reactive protein in tubulointerstitial nephritis and uveitis syndrome.

K Jakuszko1, M Krajewska, A Hałoń, K Kościelska-Kasprzak, M Myszka, M Żabińska, H Augustyniak-Bartosik, D Rukasz, W Weyde, M Klinger.   

Abstract

Antibodies against monomeric C-reactive protein, which is a target antigen expressed both in kidney tubules and uveal cells, have been recently detected in patients with active tubulointerstitial nephritis and uveitis syndrome. We report the case of an 65-year-old woman with acute renal failure caused by biopsy-proven tubulointerstitial nephritis and the onset of uveitis 21 months later. The expression of monomeric C-reactive protein in kidney oligobiopsy was confirmed by immunohistochemical staining using mouse monoclonal antibody against human monomeric C-reactive protein. The levels of antibodies against monomeric C-reactive protein were 117% of the reference during the flare and 22% during the remission of the disease. The difference in the levels of antibodies against monomeric C-reactive protein during flare and remission, and above all positive biopsy staining, supports their pathogenic role in this disease.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  autoantibodies; monomeric CRP; tubulointerstitial nephritis; uveitis

Mesh:

Substances:

Year:  2014        PMID: 25081046     DOI: 10.1111/imj.12501

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  2 in total

1.  Serum anti-CRP antibodies differentiate etiology and predict relapse in acute tubulointerstitial nephritis.

Authors:  Jun-Wen Huang; Tao Su; Ying Tan; Jin-Wei Wang; Jia-Wei Tang; Su-Xia Wang; Gang Liu; Ming-Hui Zhao; Li Yang
Journal:  Clin Kidney J       Date:  2021-07-06

Review 2.  The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus.

Authors:  Helena Enocsson; Jesper Karlsson; Hai-Yun Li; Yi Wu; Irving Kushner; Jonas Wetterö; Christopher Sjöwall
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.